证券日报网讯1月22日，基蛋生物（603387）在互动平台回答投资者提问时表示，公司近年来持续布局 欧盟市场并开展相关业务。从业务占比来看，欧盟地区业务收入在公司整体营业收入中占比较小，但其 在公司海外营业收入中占据一定份额，是公司国际化布局的重要组成部分，未来发展潜力有待进一步挖 掘。目前，公司主要通过经销商网络拓展、客户实地考察及国际展会参与方式深化欧盟市场开发。未 来，公司将持续推进全球化发展战略，在稳固现有合作基础的前提下，积极探索更高效的市场开拓与业 务合作模式，推动海外业务高质量发展。 ...

Core Viewpoint - The company has been actively implementing an internationalization strategy across various dimensions, including innovation research and development, licensing, production operations, and commercialization, to enhance operational efficiency and strengthen its global market presence [1] Group 1: International Market Strategy - The company has established a significant presence in overseas markets, primarily covering the United States, Europe, Africa, India, and Southeast Asia [1] - In the European Union market, the company employs a diversified sales model [1] Group 2: Pharmaceutical Sector - In the pharmaceutical sector, biosimilars are developed and produced in China, with distribution to the EU market through overseas partners [1] - The injectable business primarily operates on a B2B model, supplying EU customers from manufacturing bases in India and Europe [1] Group 3: Medical Devices Sector - In the medical devices sector, the company utilizes a combination of distribution and direct sales to cover the EU market [1]

投资者提问：董秘你好 对比同行业可比公司（如振德医疗、奥美医疗），公司营收规模、业务布局均 有优势，但股价走势却长期弱势，请问公司认为自身估值折价的核心原因是什么？能否积极重视投资感 受 ？ 稳健医疗回复：尊敬的投资者，您好！稳健集团以"呵护健康、关爱生命、保护环境，让世界更美好"为 愿景，旗下拥有"winner 稳健医疗"和"Purcotton 全棉时代"两大主品牌。近年来，公司始终致力于提升经 营业绩和股东价值，产品力和品牌力逐步得到市场广泛认可，美誉度越来越高，随着核心竞争力的增 强，公司未来前景越来越广阔！另外公司通过现金分红、回购股份、董监高增持等方式，维护公司市 值。公司一直重视保障股东投资利益，希望通过良好的经营成绩回报股东的支持。感谢您的关注与支 持。 证券之星消息，稳健医疗(300888)01月22日在投资者关系平台上答复投资者关心的问题。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 ...

三诺生物回复：您好！公司自2022年起前瞻性提出深度布局AI的战略，开启从"中国血糖仪普及推动 者"向"全球领先的糖尿病数字管理专家"的数智化转型，核心是依托积累的医疗检验数据沉淀，构建标 准化数据资产体系及垂直场景专用AI模型矩阵（如餐后血糖评价、AGP血糖特征定位等专有模型）， 为多医疗场景提供定制化解决方案。公司已围绕血糖监测及糖尿病管理生态展开系统性布局，并完成物 联网技术部署，实现"设备-患者-医护人员"的互联互通，为AI技术的场景化应用提供数据传输与交互支 撑。基于此，公司推出智慧糖尿病管理系统及基于AI大模型的糖尿病专科智能体。该智能体将能全面 覆盖风险评估、方案制定、监测随访、疗效评估等糖尿病全流程，从而实现B端与C端双向赋能。在B端 医疗机构场景，有效辅助医生决策，提升慢病管理的精准度与效率；在C端居家场景，通过饮食图片识 别、智能体交互问询，帮助患者进行生活方式管理，实现从数据监测到行为干预的落地。目前，公司 AI 技术应用与商业化仍处于持续迭代优化阶段，未来，公司将持续探索"生物传感+人工智能+医疗"新 模式，深化AI技术在慢病管理领域的应用，以实现"感知+评估+干预"的糖尿病智慧管理闭 ...

1月21日，网民反映从线上旗舰店购买了初医生医用口罩，使用时在口罩内层中发现苍蝇尸体。 1月22日，口罩生产企业工作人员表示，已安排调查监控，排查具体原因。该工作人员称将联系买家协 商，将按《消费者权益保护法》规定赔付，也会综合买家需求，把事情处理好。生产企业所在辖区市监 部门工作人员表示，将到场核实情况。 新京报记者 苗玉薪 实习生 陈雨欣 制作 礼牧周 ...

Core Viewpoint - The financial performance of Kaili Medical (300633) shows mixed results, with revenue growth but significant declines in net profit, indicating potential challenges ahead for the company [2]. Financial Performance - For the first three quarters of 2025, Kaili Medical reported a main revenue of 1.459 billion yuan, an increase of 4.37% year-on-year [2]. - The net profit attributable to shareholders was 33.51 million yuan, a decrease of 69.25% year-on-year [2]. - The net profit after deducting non-recurring items was 23.99 million yuan, down 72.14% year-on-year [2]. - In Q3 2025, the company achieved a single-quarter revenue of 495 million yuan, up 28.42% year-on-year [2]. - The single-quarter net profit attributable to shareholders was -13.52 million yuan, an increase of 78.05% year-on-year [2]. - The single-quarter net profit after deducting non-recurring items was -15.89 million yuan, an increase of 76.92% year-on-year [2]. - The company's debt ratio stands at 24.22%, with investment income of 2.08 million yuan and financial expenses of -38.30 million yuan [2]. - The gross profit margin is reported at 60.36% [2]. Market Activity - As of January 22, 2026, Kaili Medical's stock closed at 28.11 yuan, with a slight increase of 0.14% [1]. - The turnover rate was 0.7%, with a trading volume of 30,100 hands and a transaction amount of 84.89 million yuan [1]. - On January 22, the net inflow of main funds was 3.33 million yuan, accounting for 3.93% of the total transaction amount [1]. - Retail investors experienced a net outflow of 4.20 million yuan, representing 4.94% of the total transaction amount [1]. Analyst Ratings - In the last 90 days, 10 institutions provided ratings for Kaili Medical, with 8 giving a "buy" rating and 2 giving an "accumulate" rating [2]. - The average target price set by institutions over the past 90 days is 39.71 yuan [2].

Core Viewpoint - The stock of Dabo Medical (002901) has shown a decline in price and mixed capital flow, indicating potential volatility in investor sentiment and market performance [1][3]. Group 1: Stock Performance - As of January 22, 2026, Dabo Medical's stock closed at 49.42 yuan, down 1.06% with a turnover rate of 0.58% and a trading volume of 16,800 lots, amounting to a transaction value of 83.36 million yuan [1]. - The net outflow of main funds on January 22 was 1.92 million yuan, accounting for 2.31% of the total transaction value, while retail investors saw a net inflow of 1.26 million yuan, representing 1.51% of the total [1]. Group 2: Financial Metrics and Industry Comparison - Dabo Medical's total market capitalization is 20.461 billion yuan, significantly higher than the industry average of 11.31 billion yuan, ranking 12th out of 127 companies in the medical device sector [2]. - The company reported a net profit of 425 million yuan for the first three quarters of 2025, a year-on-year increase of 77.03%, with a gross margin of 71.23%, which is well above the industry average of 50.94% [2]. - The company's return on equity (ROE) stands at 12.83%, placing it 7th in the industry, while its price-to-earnings ratio (P/E) is 36.14, significantly lower than the industry average of 97.34 [2].

Core Viewpoint - Changhong Technology emphasizes the accuracy and completeness of its periodic reports, asserting no false records or misleading statements exist, and projects a revenue of 743 million yuan for the first three quarters of 2025 [2] Group 1: Financial Performance - The company achieved a revenue of 129 million yuan from medical devices and consumables in the first half of 2025, with a gross margin of 35.64% [2] - The total revenue for the first three quarters of 2025 is projected to be 743 million yuan [2] Group 2: Market Position - Changhong Technology supplies high polymer consumables such as reaction cups and Tip heads to domestic and global IVD giants, with an annual supply quantity exceeding 1 billion units [2]

Group 1 - The company, Shanghai Haili Biological Technology Co., Ltd., announced that its wholly-owned subsidiary, Shanghai Jiemen Biotechnology Co., Ltd., has received a renewed Medical Device Manufacturing License from the Shanghai Municipal Drug Administration [2] - The renewal extends the license validity until January 3, 2031, and changes the production address to "Room 102, 202, 502, No. 66, Hengyu Road, Jiading District, Shanghai" [2]

Group 1 - The company, Changhong Technology, has completed the main construction of its high-end medical equipment and consumables base in South China, with some cleanroom renovations nearing completion and production equipment being installed and debugged [1] - The headquarters renovation and upgrade project has seen the completion of the dormitory main structure and renovations, making it ready for occupancy [1] - The renovation of the old factory within the headquarters upgrade project has also been completed, with office renovations currently underway [1] - In Vietnam, the CN11 factory construction project has one building and one comprehensive building completed, with internal renovations ongoing and some production equipment already moved in [1]